For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...
Medpage Today on MSN2d
More Progress for Bladder-Sparing Strategies in Muscle-Invasive CancerNeoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
A phase II clinical trial found that combining radiotherapy with immune checkpoint inhibitors (durvalumab and tremelimumab) ...
Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...
UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 ...
Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the ...
MRI for the initial staging of MIBC is both feasible and beneficial in reducing treatment delays compared to TURBT, a new study shows.
ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback